This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ahrén, B. Articles by Efendic, S. Search for Related Content PubMed PubMed Citation Articles by Ahrén, B. Articles by Efendic, S.

Antidiabetogenic Action of Cholecystokinin-8 in Type 2 Diabetes¹

Department of Medicine, Lund University (B.A.), S-205 02Malmo, Sweden; Department of Endocrinology and Metabolism, Panum Institute (J.J.H.), Copenhagen, Denmark; and Department of Molecular Medicine, Karolinska Institute (S.E.), S-171 77 Stockholm, Sweden

Address all correspondence and requests for reprints to: Dr. Bo Ahrén, Department of Medicine, Malmo University Hospital, S-205 02 Malmo, Sweden.

Cholecystokinin (CCK) is a gut hormone and a neuropeptide that has the capacity to stimulate insulin secretion. As insulin secretion is impaired in type 2 diabetes, we explored whether exogenous administration of this peptide exerts antidiabetogenic action. The C-terminal octapeptide of CCK (CCK-8) was therefore infused iv (24 pmol/kg·h) for 90 min in six healthy postmenopausal women and in six postmenopausal women with type 2 diabetes. At 15 min after start of infusion, a meal was served and ingested during 10 min. On a separate day, saline was infused instead of CCK-8. In both healthy subjects and subjects with type 2 diabetes, CCK-8 reduced the increase in circulating glucose after meal ingestion and potentiated the increase in circulating insulin. The ratio between the area under the curves for serum insulin and plasma glucose during the 15- to 75-min period after meal ingestion was increased by CCK-8 by 198 ± 18% in healthy subjects (P = 0.002) and by 474 ± 151% (P = 0.038) in subjects with type 2 diabetes. In contrast, the increase in the circulating levels of gastric inhibitory polypeptide (GIP), glucagon-like peptide-1 (GLP-1), or glucagon after meal ingestion was not significantly affected by CCK-8. The study therefore shows that CCK-8 exerts an antidiabetogenic action in both healthy subjects and type 2 diabetes through an insulinotropic action that most likely is exerted trough a direct islet effect. As at the same time, CCK-8 was infused without any adverse effects, the study suggests that CCK is a potential treatment for type 2 diabetes.

This article has been cited by other articles:

				M. O. Weickert, M. Mohlig, J. Spranger, C. Schofl, C. V. Loeffelholz, R. L. Riepl, B. Otto, and A. F. H. Pfeiffer Effects of Euglycemic Hyperinsulinemia and Lipid Infusion on Circulating Cholecystokinin J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2328 - 2333. [Abstract] [Full Text] [PDF]

				M. Dufresne, C. Seva, and D. Fourmy Cholecystokinin and gastrin receptors. Physiol Rev, July 1, 2006; 86(3): 805 - 847. [Abstract] [Full Text] [PDF]

				J. Morisset, S. Julien, and J. Laine Localization of Cholecystokinin Receptor Subtypes in the Endocine Pancreas J. Histochem. Cytochem., November 1, 2003; 51(11): 1501 - 1513. [Abstract] [Full Text] [PDF]

				C. G. MacIntosh, J. E. Morley, J. Wishart, H. Morris, J. B. M. J. Jansen, M. Horowitz, and I. M. Chapman Effect of Exogenous Cholecystokinin (CCK)-8 on Food Intake and Plasma CCK, Leptin, and Insulin Concentrations in Older and Young Adults: Evidence for Increased CCK Activity as a Cause of the Anorexia of Aging J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5830 - 5837. [Abstract] [Full Text] [PDF]